跳到正文
原文
Endpoints News 生物医药· Reynald Castaneda·· 23 天前AI 评分33

Astellas 从 Audax Biosciences 获得临床前 IL-12 肿瘤药物独家许可选择权

Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences

AI 导读

Astellas 已从澳大利亚生物技术公司 Audax Biosciences 获得一款临床前 IL-12 肿瘤药物的独家许可选择权。这项免疫肿瘤资产交易涉及 2.85 亿美元。

正文

Astel­las has tak­en an ex­clu­sive op­tion to li­cense a pre­clin­i­cal im­muno-on­col­o­gy as­set from Aus­tralian biotech Au­dax Bio­sciences.

The deal fea­tures $285 mil­lion that cov­ers the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news